How to Get Jardiance in Nebraska: Prescriptions, Telehealth, and Pharmacy Access

What Is Jardiance and Why Nebraska Patients Are Seeking It

Jardiance is a once-daily oral tablet indicated for type 2 diabetes, heart failure with reduced or preserved ejection fraction, and chronic kidney disease. The active ingredient, empagliflozin, belongs to the sodium-glucose cotransporter-2 (SGLT2) inhibitor class. It lowers blood glucose by blocking glucose reabsorption in the proximal tubule of the kidney, causing excess glucose to be excreted in urine. [1]

The surge in Nebraska interest follows landmark outcomes data. In EMPA-REG OUTCOME (N=7,020), empagliflozin 10 mg or 25 mg reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 14% relative to placebo (10.5% vs. 12.1%; hazard ratio 0.86 to 95% CI 0.74 to 0.99; P<0.001 for noninferiority, P=0.04 for superiority) [2]. Cardiovascular death alone fell by 38% relative risk reduction [2]. Those numbers changed prescribing behavior across endocrinology, cardiology, and nephrology nationwide, including in Nebraska.

The FDA has approved empagliflozin under the brand name Jardiance for three distinct indications: type 2 diabetes mellitus (2014), heart failure (2021), and CKD (2023) [1]. Each indication carries its own dosing guidance and contraindications, so a prescriber must confirm the correct clinical context before writing the script.

The American Diabetes Association 2024 Standards of Care recommend SGLT2 inhibitors as preferred add-on therapy in patients with type 2 diabetes and established atherosclerotic cardiovascular disease, heart failure, or CKD [3]. The 2022 AHA/ACC Guideline for Heart Failure lists SGLT2 inhibitors as Class I, Level A recommendations for patients with HFrEF [4].

How to Get a Jardiance Prescription in Nebraska

Getting Jardiance in Nebraska requires three steps: a clinical evaluation, a lab workup, and a prescription routed to a licensed pharmacy. Nebraska does not require an in-person visit for telehealth prescribing of non-controlled medications under Nebraska Revised Statute 38-2142 [5]. That means a qualified provider can evaluate you via video call, review your chart, and send a prescription to any Nebraska pharmacy the same day.

The prescribing visit typically covers your current medications (metformin, GLP-1 agonists, diuretics, and ACE inhibitors all interact with empagliflozin), your cardiovascular and renal history, blood pressure readings, and any history of recurrent urinary tract infections or genital mycotic infections, the two most common side effects seen in clinical practice [6].

After the visit, expect 24 to 72 hours for the prescription to process, insurance to adjudicate, and the pharmacy to dispense. Mail-order pharmacies may add two to five business days for shipping to Nebraska zip codes. Same-day pickup is available at most major Nebraska retail chains once insurance verifies coverage.

The ADA's 2024 guidelines state directly: "For patients with type 2 diabetes and CKD, use of an SGLT2 inhibitor with proven kidney benefit is recommended to reduce CKD progression and cardiovascular events." [3] That guideline language is often cited in prior authorization appeal letters when insurers initially deny coverage.

Labs Required Before Starting Jardiance in Nebraska

Before any prescriber in Nebraska writes empagliflozin, they need a current metabolic panel to confirm kidney function is adequate. Jardiance should not be started when eGFR is below 20 mL/min/1.73 m² in the CKD indication; the FDA label specifies eGFR thresholds that differ by indication [1]. Here is the standard pre-prescribing lab framework used by the HealthRX clinical team:

Baseline labs (all indications)

• Comprehensive metabolic panel (CMP) or basic metabolic panel (BMP): sodium, potassium, creatinine, glucose
• Calculated eGFR using CKD-EPI 2021 equation [7]
• Urinalysis with microscopy (screens for active UTI, which is a temporary contraindication)
• HbA1c (type 2 diabetes indication only)

Additional labs by indication

• Heart failure: NT-proBNP or BNP at baseline, echocardiogram within 12 months
• CKD: urine albumin-to-creatinine ratio (UACR); the EMPA-KIDNEY trial (N=6,609) showed empagliflozin reduced the primary kidney composite endpoint by 28% relative to placebo regardless of diabetes status (HR 0.72 to 95% CI 0.64 to 0.82; P<0.001) [8]

Most Nebraska telehealth platforms order labs through Quest Diagnostics or LabCorp, both of which have patient service centers in Omaha, Lincoln, Grand Island, Kearney, and Scottsbluff. Results typically return within 24 to 48 hours.

Empagliflozin is not recommended for type 1 diabetes due to the risk of euglycemic diabetic ketoacidosis, a serious adverse event in which blood glucose may be normal while ketones are dangerously elevated [6]. The FDA added a class-wide warning for SGLT2 inhibitors regarding this risk [1].

Telehealth Prescribing of Jardiance in Nebraska

Nebraska permits telehealth prescribing of non-controlled medications without a prior in-person visit, provided the prescriber establishes a valid patient-provider relationship via synchronous two-way communication [5]. Empagliflozin is not a controlled substance, so no DEA special registration is required.

A telehealth prescriber licensed in Nebraska (or licensed in another state and operating under Nebraska's telehealth compact provisions) must document the same clinical information required in an office visit: chief complaint, medication history, relevant labs, and a treatment plan with follow-up interval [5]. Prescribers who skip this documentation risk license action and insurance clawbacks.

The EMPEROR-Reduced trial (N=3,730) showed empagliflozin 10 mg reduced the composite of cardiovascular death or hospitalization for heart failure by 25% relative to placebo (HR 0.75 to 95% CI 0.65 to 0.86; P<0.001) in patients with HFrEF [9]. The EMPEROR-Preserved trial (N=5,988) extended the benefit to HFpEF, with a 21% relative reduction in the primary endpoint (HR 0.79 to 95% CI 0.69 to 0.90; P<0.001) [10]. These data are specifically referenced by Nebraska cardiology practices when ordering Jardiance remotely for heart failure patients who cannot travel.

Nebraska NPs hold full practice authority under Nebraska Statute 38-2315 and do not need physician supervision to prescribe Jardiance [11]. PAs in Nebraska must have a supervising physician agreement on file but can independently prescribe non-controlled medications within that agreement. MDs and DOs have unrestricted prescribing authority. All three provider types are eligible to prescribe via telehealth under Nebraska law.

Pharmacy Access: Where to Fill Jardiance in Nebraska

Jardiance is stocked at virtually every major retail pharmacy chain operating in Nebraska, including Walgreens, CVS, Hy-Vee Pharmacy, Walmart Pharmacy, and Kroger-affiliated stores. Independent community pharmacies throughout rural Nebraska generally carry or can order 10 mg and 25 mg tablets within one business day.

Mail-order options for Nebraska residents include Express Scripts, CVS Caremark, OptumRx, and Amazon Pharmacy. Mail-order typically provides a 90-day supply, which lowers the per-pill cost under most commercial pharmacy benefit designs.

The Boehringer Ingelheim and Lilly Jardiance copay card reduces out-of-pocket cost to as low as $10 per month for eligible commercially insured patients; maximum annual savings are capped at $2,400 [1]. Patients without any insurance may access the Lilly Insulin Value Program or apply for manufacturer patient assistance at no cost if income meets eligibility thresholds.

Nebraska Medicaid (Heritage Health) does not cover Jardiance for type 2 diabetes, heart failure, or CKD as of the 2025 formulary [12]. Providers treating Medicaid patients may instead prescribe dapagliflozin (Farxiga) if it appears on the Heritage Health preferred drug list, or submit a prior authorization with clinical documentation supporting medical necessity for empagliflozin specifically.

503A Compounding Pharmacies in Nebraska for Empagliflozin

A 503A pharmacy compounds medications for individual patients based on a valid prescription from a licensed prescriber. Nebraska-licensed 503A pharmacies can compound empagliflozin capsules or suspensions for patients who have documented clinical need and a valid prescription [13]. This option is less common than retail Jardiance but is used when a patient needs a dose form or strength not commercially available, or when cost is prohibitive.

503A compounding pharmacies must comply with Nebraska Department of Health and Human Services pharmacy regulations and USP standards [13]. Compounded empagliflozin is not FDA-approved and does not carry the same bioequivalence data as the branded tablet. Patients should discuss this trade-off with their prescriber before choosing the compounded route.

The DAPA-CKD trial (N=4,304), though studying dapagliflozin rather than empagliflozin, provides supporting mechanistic context: SGLT2 inhibition reduced the primary CKD composite by 39% relative to placebo (HR 0.61 to 95% CI 0.51 to 0.72; P<0.001) [14]. This class-level evidence helps prescribers justify SGLT2 therapy to patients and payers even when the specific branded agent differs.

Prior Authorization for Jardiance in Nebraska

Most commercial insurance plans in Nebraska require prior authorization (PA) for Jardiance. The specific criteria vary by plan, but nearly all require documentation of the following:

Type 2 diabetes indication

• HbA1c of 7.0% or above on current therapy, or inability to tolerate metformin
• Trial of metformin unless contraindicated (eGFR <30, intolerance, or allergy)
• Current medication list showing at least one first-line agent was tried

Heart failure indication

• Confirmed diagnosis of HFrEF (ejection fraction at or below 40%) or HFpEF
• Current guideline-directed medical therapy including ACE inhibitor or ARB plus beta-blocker

CKD indication

• eGFR 20 to 45 mL/min/1.73 m² with UACR 200 mg/g or above, or eGFR 45 to 90 with UACR 200 mg/g or above
• Documentation that kidney function has been declining or proteinuria is present

Appeals for denied PAs can cite the EMPA-REG OUTCOME [2], EMPEROR-Reduced [9], EMPEROR-Preserved [10], and EMPA-KIDNEY [8] trials directly. The ADA 2024 Standards of Care state: "Optimizing medication selection to reduce risk of CKD progression, cardiovascular events, and hypoglycemia is critical in people with type 2 diabetes and CKD." [3] Many Nebraska commercial plans overturn denials when clinical documentation includes the specific eGFR and UACR values alongside a trial citation.

Processing time for PA requests in Nebraska typically runs five to ten business days for standard review and 24 to 72 hours for urgent or expedited review when the prescriber documents clinical urgency [15].

Transferring a Jardiance Prescription to Nebraska

Jardiance is not a controlled substance, so Nebraska law does not restrict the number of times a prescription can be transferred between licensed pharmacies [16]. A patient moving from another state or switching pharmacies within Nebraska can ask the receiving pharmacy to contact the dispensing pharmacy and complete an electronic or phone transfer.

For transfers from out-of-state providers, the prescription must comply with Nebraska's valid prescription requirements: date, patient name, drug name and strength, quantity, directions, prescriber name and license number, and DEA number if applicable [16]. Empagliflozin does not require a DEA number.

Refills on a transferred prescription follow the original prescriber's refill authorization. If that authorization has expired or the prescriber is out-of-network, the receiving Nebraska pharmacy can dispense an emergency 30-day supply in some circumstances, but a new prescriber relationship is the cleanest path forward.

Cost Management Strategies for Nebraska Patients

Jardiance carries a manufacturer list price of approximately $618 to $635 per month for a 30-day supply of either 10 mg or 25 mg tablets as of 2025 [1]. Several strategies reduce this cost significantly.

The Jardiance copay card (Boehringer Ingelheim) brings the monthly out-of-pocket cost to $10 for commercially insured patients up to the annual $2,400 cap [1]. GoodRx and similar discount programs negotiate rates with individual Nebraska pharmacies and may offer prices in the $400 to $500 range for uninsured patients, though these vary by pharmacy location and change frequently.

The SOLOIST-WHF trial (N=1,222) studied sotagliflozin (a dual SGLT1/SGLT2 inhibitor) in acute decompensated heart failure and found a 33% relative reduction in the primary endpoint versus placebo [17], reinforcing the class evidence even in acute settings. While this trial does not directly support empagliflozin cost arguments, it demonstrates the clinical value of the mechanism that payers and patient assistance reviewers recognize.

Patients below 400% of the federal poverty level who are uninsured or underinsured may qualify for the Lilly Cares Foundation patient assistance program, which can provide Jardiance at no charge [1]. Applications require proof of income, insurance status, and a physician attestation.

Follow-Up and Monitoring After Starting Jardiance in Nebraska

Starting empagliflozin is not a one-visit event. The FDA label recommends monitoring eGFR at baseline, at initiation, and periodically thereafter, with frequency depending on the degree of renal impairment [1]. For CKD patients, the Kidney Disease Improving Global Outcomes (KDIGO) 2022 guidelines recommend eGFR and UACR monitoring at least annually and more frequently if eGFR is below 30 [18].

A transient dip in eGFR of 2 to 5 mL/min/1.73 m² is expected in the first four to eight weeks of therapy and does not require discontinuation. This hemodynamic effect is actually associated with longer-term nephroprotection, as confirmed in the EMPA-KIDNEY trial [8]. Prescribers in Nebraska should document this expected finding and counsel patients so they do not discontinue the medication prematurely.

Blood pressure typically decreases by 3 to 5 mmHg systolic in the first four weeks, which may require adjustment of existing antihypertensive medications [6]. Genital mycotic infections occur in approximately 6% of women and 3% of men on empagliflozin [6]. Most cases are mild and respond to topical antifungal therapy without stopping the drug.

Patients traveling within Nebraska or to other states should carry a medication list identifying empagliflozin by generic name, since pharmacists can look up the branded or generic form regardless of which name appears on the prescription.